

Jose Martinez-Raga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3763286/publications.pdf>

Version: 2024-02-01

87
papers

37,603
citations

159585

30
h-index

85541

71
g-index

102
all docs

102
docs citations

102
times ranked

63388
citing authors

#	ARTICLE	IF	CITATIONS
1	A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment. <i>Neuropsychiatric Disease and Treatment</i> , 2022, Volume 18, 965-976.	2.2	1
2	Structure and Functioning of Acute Inpatient Psychiatric Units in Spain: Qualitative Study. <i>JMIR Research Protocols</i> , 2021, 10, e26214.	1.0	0
3	Subgroups of Children with Autism Spectrum Disorder without Intellectual Disability: A Longitudinal Examination of Executive and Socio-Adaptive Behaviors in Adolescence. <i>Journal of Clinical Medicine</i> , 2021, 10, 2220.	2.4	3
4	Developmental outcomes in adolescence of children with autism spectrum disorder without intellectual disability: A systematic review of prospective studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 126, 590-603.	6.1	7
5	Use of Antipsychotics in Patients with Behavioral and Psychological Symptoms of Dementia: Results of a Spanish Delphi Consensus. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 573-582.	1.5	5
6	Empirical examination of executive functioning, ADHD associated behaviors, and functional impairments in adults with persistent ADHD, remittent ADHD, and without ADHD. <i>BMC Psychiatry</i> , 2020, 20, 134.	2.6	22
7	Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study. <i>Drugs - Real World Outcomes</i> , 2020, 7, 75-83.	1.6	16
8	Large expert-curated database for benchmarking document similarity detection in biomedical literature search. <i>Database: the Journal of Biological Databases and Curation</i> , 2019, 2019, .	3.0	15
9	Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 47-61.	2.3	9
10	The burden of mental disorders in the Eastern Mediterranean region, 1990â€“2015: findings from the global burden of disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 25-37.	2.3	43
11	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1684-1735.	13.7	716
12	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	13.7	638
13	1st International Expertsâ€™ Meeting on Agitation: Conclusions Regarding the Current and Ideal Management Paradigm of Agitation. <i>Frontiers in Psychiatry</i> , 2018, 9, 54.	2.6	32
14	La carga de enfermedad en EspaÃ±a: resultados del Estudio de la Carga Global de las Enfermedades 2016. <i>Medicina ClÃnica</i> , 2018, 151, 171-190.	0.6	113
15	Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis. <i>BMC Psychiatry</i> , 2018, 18, 40.	2.6	32
16	Alcohol use and burden for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 392, 1015-1035.	13.7	2,005
17	Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 629-633.	1.6	25
18	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€“2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 390, 231-266.	13.7	480

#	ARTICLE	IF	CITATIONS
19	Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 389, 1885-1906.	13.7	1,281
20	Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes. <i>Therapeutic Advances in Drug Safety</i> , 2017, 8, 87-99.	2.4	27
21	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1084-1150.	13.7	573
22	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1260-1344.	13.7	1,589
23	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1151-1210.	13.7	3,565
24	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1211-1259.	13.7	5,578
25	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1345-1422.	13.7	1,879
26	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1423-1459.	13.7	284
27	The Role of Education on Dual Disorders: A Discussion Paper. <i>Addictive Disorders and Their Treatment</i> , 2017, 16, 155-163.	0.5	0
28	Hepatitis C Cr3nica y usuarios con un historial de inyecci3n de drogas en Espa3a: evaluaci3n de la poblaci3n, retos para un tratamiento efectivo.. <i>Revista De Psicología De La Salud</i> , 2017, 29, 71.	0.5	9
29	Nonmedical use of prescription drugs in the European Union. <i>BMC Psychiatry</i> , 2016, 16, 274.	2.6	137
30	State of Training, Clinical Services, and Research on Dual Disorders Across France, India, Israel, and Spain. <i>Journal of Dual Diagnosis</i> , 2016, 12, 252-260.	1.2	11
31	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1603-1658.	13.7	1,612
32	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1459-1544.	13.7	4,934
33	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1545-1602.	13.7	5,298
34	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1659-1724.	13.7	4,203
35	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	13.7	571
36	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	13.7	413

#	ARTICLE	IF	CITATIONS
37	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. <i>Lancet HIV</i> , 2016, 3, e361-e387.	4.7	461
38	Clinical guideline for the treatment of dual pathology in the adult population. <i>Revista De Psicología De La Salud</i> , 2016, 28, 3.	0.5	5
39	Relevant Differences in Perception and Knowledge of Professionals in Different Spanish Autonomous Communities Regarding Availability of Resources for Patients with Dual disorders. <i>Actas Espanolas De Psiquiatria</i> , 2016, 44, 1-12.	0.1	0
40	Who says this is a modern disorder? The early history of attention deficit hyperactivity disorder. <i>World Journal of Psychiatry</i> , 2015, 5, 379.	2.7	18
41	Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1359.	2.2	11
42	Attention-deficit hyperactivity disorder (ADHD), substance use disorders, and criminality: a difficult problem with complex solutions. <i>International Journal of Adolescent Medicine and Health</i> , 2015, 27, 163-175.	1.3	41
43	Dual Diagnosis Resource Needs in Spain: A National Survey of Professionals. <i>Journal of Dual Diagnosis</i> , 2014, 10, 84-90.	1.2	15
44	Professionals'™ perceptions about healthcare resources for co-occurring disorders in Spain. <i>International Journal of Mental Health Systems</i> , 2014, 8, 35.	2.7	5
45	Validation of the Spanish version of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). <i>Psicothema</i> , 2014, 26, 180-5.	0.9	18
46	Risk of Serious Cardiovascular Problems with Medications for Attention-Deficit Hyperactivity Disorder. <i>CNS Drugs</i> , 2013, 27, 15-30.	5.9	109
47	Attention deficit hyperactivity disorder and dual disorders. Educational needs for an underdiagnosed condition. <i>International Journal of Adolescent Medicine and Health</i> , 2013, 25, 231-243.	1.3	28
48	Rethinking Dual Disorders/Pathology. <i>Addictive Disorders and Their Treatment</i> , 2013, 12, 1-10.	0.5	34
49	Addressing Dual Diagnosis Patients Suffering from Attention-Deficit Hyperactivity Disorders and Comorbid Substance Use Disorders. <i>Addictive Disorders and Their Treatment</i> , 2013, 12, 213-230.	0.5	10
50	Nutritional Education of Secondary Education Students and Diet Quality. , 2013, , 207-218.		0
51	13. Attention-deficit hyperactivity disorder and dual disorders: educational needs for an underdiagnosed condition. , 2013, , 151-172.		0
52	Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain. <i>Health Economics Review</i> , 2012, 2, 3.	2.0	5
53	PMH16 Budgetary Impact Analysis of Buprenorphine/Naloxone (Suboxone®) in Opioid Maintenance Treatment in Spain. <i>Value in Health</i> , 2011, 14, A289.	0.3	0
54	Consumo adictivo de sustancias psicoactivas. <i>Medicine</i> , 2011, 10, 5800-5809.	0.0	0

#	ARTICLE	IF	CITATIONS
55	A Review of "Encounter Groups for Addictions: The Therapeutic Community Training Series" Journal of Groups in Addiction and Recovery, 2011, 6, 338-338.	0.4	0
56	Gluten as a precipitating factor of autoimmune diseases other than celiac disease. Proceedings of the Nutrition Society, 2010, 69, .	1.0	0
57	Suboxone® (Buprenorphine/Naloxone) as an Agonist Opioid Treatment in Spain: A Budgetary Impact Analysis. European Addiction Research, 2010, 16, 31-42.	2.4	15
58	Alcohol consumption in secondary-school students: effects on plasma total antioxidant capacity. Proceedings of the Nutrition Society, 2008, 67, .	1.0	0
59	Influence of fruit intake and antioxidants on the prevention of opacities of the lens. Proceedings of the Nutrition Society, 2008, 67, .	1.0	0
60	Modafinil: A Useful Medication for Cocaine Addiction? Review of the Evidence from Neuropharmacological, Experimental and Clinical Studies. Current Drug Abuse Reviews, 2008, 1, 213-221.	3.4	47
61	Antipsychotic Drug Treatment of Schizophrenic Patients with Substance Abuse Disorders. European Addiction Research, 2007, 13, 230-243.	2.4	35
62	One session of high frequency repetitive transcranial magnetic stimulation (rTMS) to the right prefrontal cortex transiently reduces cocaine craving. Drug and Alcohol Dependence, 2007, 86, 91-94.	3.2	228
63	Does Anyone Care about Names? How Attendees at Substance Misuse Services Like to Be Addressed by Health Professionals. European Addiction Research, 2004, 10, 75-79.	2.4	13
64	Add-on gabapentin in the treatment of opiate withdrawal. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 599-601.	4.8	46
65	The role of personality disorders on drug dependence treatment outcomes following inpatient detoxification. European Psychiatry, 2004, 19, 187-192.	0.2	23
66	Anorgasmia in a Patient Treated With Bupropion SR for Smoking Cessation. Journal of Clinical Psychopharmacology, 2004, 24, 460-461.	1.4	7
67	Atención y craving o ganas compulsivas. Avances en su conceptualización y su implicación en la prevención de recaídas. Revista De Psicología De La Salud, 2004, 20, 365.	0.5	2
68	Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile. Addiction Biology, 2003, 8, 13-21.	2.6	27
69	Homosexual Delusional Jealousy in Two Heterosexual Women. Psychopathology, 2003, 36, 33-36.	1.5	2
70	Complicaciones físicas del consumo de drogas recreativas. Revista De Psicología De La Salud, 2003, 15, 207.	0.5	0
71	News and Notes: 2. Addiction, 2003, 98, 862-863.	3.3	0
72	UNPLANNED VERSUS PLANNED DISCHARGES FROM IN-PATIENT ALCOHOL DETOXIFICATION: RETROSPECTIVE ANALYSIS OF 470 FIRST-EPISEODE ADMISSIONS. Alcohol and Alcoholism, 2002, 37, 277-281.	1.6	66

#	ARTICLE	IF	CITATIONS
73	Positive or negative history of childhood sexual abuse among problem drinkers: relationship to substance use disorders and psychiatric co-morbidity. <i>Journal of Substance Use</i> , 2002, 7, 34-40.	0.7	1
74	Use of gabapentin in the treatment of opiate withdrawal. A case series. <i>European Neuropsychopharmacology</i> , 2002, 12, 394.	0.7	0
75	Interest in smoking cessation in a sample of Spanish alcohol and drug dependent patients. <i>European Neuropsychopharmacology</i> , 2002, 12, 399.	0.7	0
76	Personalidades impulsivas y trastornos por uso de sustancias: algo más que un diagnóstico dual. <i>Trastornos Adictivos</i> , 2002, 4, 216-222.	0.1	4
77	Extrahepatic effects of alcohol: an overview. , 2002, , 467-485.		1
78	Los trastornos relacionados con el uso de sustancias desde la perspectiva de la psicopatología y las neurociencias. <i>Trastornos Adictivos</i> , 2001, 3, 164-171.	0.1	8
79	Hepatitis B and C in alcohol-dependent patients admitted to a UK alcohol inpatient treatment unit. <i>Addiction Biology</i> , 2001, 6, 363-372.	2.6	12
80	Impact of family history of alcoholism on cocaine-induced subjective effects and pharmacokinetic profile. <i>Psychopharmacology</i> , 2000, 152, 268-274.	3.1	8
81	What Makes Alcohol-Dependent Individuals Early in Abstinence Crave for Alcohol: Exposure to the Drink, Images of Drinking, or Remembrance of Drinks Past?. <i>Alcoholism: Clinical and Experimental Research</i> , 1998, 22, 1376-1381.	2.4	25
82	Gender differences in cocaine dependent patients: a 6 month follow-up study. <i>Drug and Alcohol Dependence</i> , 1997, 44, 35-40.	3.2	110
83	Subjective and behavioral responses and event related potentials following cocaine administration in subjects with and without a family history of alcoholism. <i>European Psychiatry</i> , 1996, 11, 299s.	0.2	0
84	Personality disorders in a sample of Spanish drug dependent patients admitted for inpatient detoxification. <i>European Psychiatry</i> , 1996, 11, 321s-322s.	0.2	0
85	Psychiatric comorbidity among opiate dependent patients in a methadone maintenance program. <i>European Psychiatry</i> , 1996, 11, 331s-332s.	0.2	0
86	The Significance of a Coexisting Opioid Use Disorder in Cocaine Dependence: An Empirical Study. <i>American Journal of Drug and Alcohol Abuse</i> , 1996, 22, 173-184.	2.1	13
87	Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder. <i>OncoTargets and Therapy</i> , 0, , 1359.	2.0	0